Furthermore, there is also a lack of standardization regarding determination of ATRX loss in tumours like gliomas, where specific thresholds for positive ATRX expression detected by IHC are not well enforced and vary between studies [78]. The gene discussed is ATRX; the disease is central nervous system cancer.